From 2024 to 2025, the global continuous glucose monitoring (CGM) industry will exhibit a trend of technological innovation and strengthened compliance. In the international market, the US healthcare system continues to expand, with Medicare covering all insulin dependent patients and commercial insurance introducing a blood glucose control linked premium model; The EU has strengthened regulatory requirements, requiring CGM products to pass MDR certification and submit real-world research data. The localized storage of data under GDPR regulations has pushed up compliance costs for enterprises.
On the technical level, the UK has launched microwave sensing non-invasive CGM into clinical practice, and domestic companies such as Meiqi Medical have achieved technological breakthroughs in 14 day wearing and MARD values below 9%. Industry standards are being upgraded synchronously, and CGM performance evaluation guidelines are being updated in multiple countries, emphasizing accuracy and data security. The global market presents a pattern of "European and American dominance, Asia Pacific rise". The EU market size is expected to reach 3.2 billion US dollars by 2025, while China and other Asia Pacific markets have become the core engines of growth with a growth rate of over 27%.
